Open AccessImmunotherapy in the landscape of new targeted treatments for non‐small cell lung cancer
Author(s) -
Gérard Catherine,
Debruyne Channa
Publication year - 2009
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2009.09.001
Subject(s) - lung cancer , immunotherapy , context (archaeology) , medicine , tyrosine kinase , clinical trial , oncology , receptor tyrosine kinase , cancer , cancer research , biology , receptor , paleontology
Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related death worldwide. Active immunotherapies and molecules targeting tyrosine kinase receptors both offer new avenues for the treatment of NSCLC. Furthermore, their combinations or their administration along with standard treatments enlarges the potential for clinical benefit. Moreover, the discovery of biomarkers predicting the response to these new therapies should allow a better selection of patients susceptible to optimally benefit from these treatments. In this paper, we review the most promising active immunotherapies, antibodies and small molecules in the context of NSCLC management, focusing on compounds in phase III clinical development.